Witnessing the stock’s movement on the chart, on Wednesday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) set off with pace as it heaved 10.29% to $1.50, before settling in for the price of $1.36 at the close. Taking a more long-term approach, ZNTL posted a 52-week range of $1.01-$11.91.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its Annual Earning per share during the time was -12.89%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 3.75%. This publicly-traded company’s shares outstanding now amounts to $71.95 million, simultaneously with a float of $55.63 million. The organization now has a market capitalization sitting at $107.93 million. At the time of writing, stock’s 50-day Moving Average stood at $1.3388, while the 200-day Moving Average is $2.5227.
Zentalis Pharmaceuticals Inc (ZNTL) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Zentalis Pharmaceuticals Inc’s current insider ownership accounts for 22.69%, in contrast to 76.55% institutional ownership. According to the most recent insider trade that took place on Apr 30 ’25, this organization’s Director bought 21,000 shares at the rate of 1.40, making the entire transaction reach 29,373 in total value, affecting insider ownership by 281,192. Preceding that transaction, on Feb 06 ’25, Company’s Chief Medical Officer bought 20,000 for 2.28, making the whole transaction’s value amount to 45,656. This particular insider is now the holder of 36,629 in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Revenue Records
Zentalis Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 3.75% and is forecasted to reach -1.98 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 7.04% through the next 5 years, which can be compared against the -12.89% growth it accomplished over the previous five years trading on the market.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Let’s observe the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). It’s Quick Ratio in the last reported quarter now stands at 6.94. The Stock has managed to achieve an average true range (ATR) of 0.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.02.
In the same vein, ZNTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.15, a figure that is expected to reach -0.53 in the next quarter, and analysts are predicting that it will be -1.98 at the market close of one year from today.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Going through the that latest performance of [Zentalis Pharmaceuticals Inc, ZNTL]. Its last 5-days volume of 1.22 million was inferior to the volume of 1.37 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 86.29% While, its Average True Range was 0.1007.
Raw Stochastic average of Zentalis Pharmaceuticals Inc (ZNTL) in the period of the previous 100 days is set at 23.90%, which indicates a major fall in contrast to 97.14% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 64.97% that was lower than 105.19% volatility it exhibited in the past 100-days period.
